Incyte Corporation (INCY)

89.31
NASDAQ
Prev Close 87.76
Day Low/High 87.77 / 89.89
52 Wk Low/High 62.48 / 110.36
Exchange NASDAQ
Shares Outstanding 218.70B
Market Cap 19.19B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: 20 Stocks That Are Emblematic of What's Driving the Market

Jim Cramer: 20 Stocks That Are Emblematic of What's Driving the Market

This list is not a buy list but a list of stocks that have been brought to new heights.

Upgrades/Downgrades

Amid the sea of news hitting the tape this morning, here's a short list of Upgrades and Downgrades.  Upgrades: International Flavors upgraded to Overweight from Equal Weight at Wells Fargo; Target raised to $150 Juniper Networks upgraded to Buy from...

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

These two firms have successful drugs and could make nice additions for larger companies.

Incyte Rated New Hold at Stifel

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Incyte Rated New Neutral at Cantor

Interesting Statistics

Some interesting statistics on the day: * Bitcoin is trading at $8.240, for a gain of nearly three percent today.  * CNN's Fear and Greed Indicator stands at a neutral 49.  * Gold is -$17.70, a drop of -1.4%. * Lumber is -$10, a -2.3% decline. * 3M ...

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

Geron Shares Rise on Fast Track Designation -- Biotech Movers

Geron Shares Rise on Fast Track Designation -- Biotech Movers

The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.

MacroGenics Soars on Collaboration with Incyte -- Biotech Movers

MacroGenics Soars on Collaboration with Incyte -- Biotech Movers

MacroGenics and Incyte on Wednesday unveiled a collaboration and license agreement regarding MGA012, MacroGenics' investigational monoclonal antibody that inhibits programmed cell death protein 1.

These Stocks Have Changed Direction

These Stocks Have Changed Direction

Finding bullish and bearish reversals in the market.

Cramer: There Should Be More Takeovers Where These Came From

Cramer: There Should Be More Takeovers Where These Came From

Buying's good for the acquirers, which should give other companies ideas.

Cramer: Let Loose the Growth Hounds

Cramer: Let Loose the Growth Hounds

Day 2 of the selloff brings in an entirely new kind of buyer.

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Stocks remained in positive territory breaking a three-day losing streak ahead of U.S. corporate earnings this week, despite mounting tension between North Korea and the U.S.

Takeaways and Observations (3PM Edition)

I started the day with an important piece on bonds - at least I hope so. Sell 'em, short 'em!    Trade of the Week - long TBT (consistent with above).  Well off the opening, at $37.60 now - and that's a good thing.   So far, so good.  At 230PM yield...

Stocks That Are Changing Direction

Stocks That Are Changing Direction

These charts are showing bullish or bearish reversals.

Cramer: Have Faith in International Strength

Cramer: Have Faith in International Strength

Because there are other things that will take the wind out of your sails.

Incyte Cut to Neutral at Piper Jaffray

Here Is Why Jim Cramer Is Bullish on Incyte

Here Is Why Jim Cramer Is Bullish on Incyte

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is fond of Incyte INCY shares.

The Good, the Bad and the Ugly (Mid-Afternoon Edition)

"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as its vacation time at the Kass household and I want to take a swim with my fam...

Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments

Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments

'These companies are all assessing the Trump effect,' Cramer said.